

July 22, 2025

SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director,
President and Chief Executive Officer
Takaaki Fukushima
Executive Corporate Officer and Chief Financial Officer
TEL: +81-3-5472-1125

Notice Concerning the Treatment of the 58th Stock Acquisition Rights in Light of the Issuance of the 65th to 67th Stock Acquisition Rights

As resolved at the meeting of the Board of Directors of SymBio Pharmaceuticals Limited held on July 22, 2025, the Company will issue the 65th, 66th, and 67th Series of Stock Acquisition Rights (collectively, the “Newly Issued Stock Acquisition Rights”) through a third-party allotment to EVO FUND. As a result of this issuance, the exercise price of the previously issued 58th Series of Stock Acquisition Rights (the “58th Stock Acquisition Rights”) will be adjusted in line with the exercise price revisions of the Newly Issued Stock Acquisition Rights, pursuant to Item 10, Clause (1) and Clause (2)-3 of the terms of issuance of the 58th Stock Acquisition Rights. Consequently, the 58th Stock Acquisition Rights are now deemed to constitute “MSCB, etc.” as defined under Article 410 of the Securities Listing Regulations established by the Tokyo Stock Exchange.

For further details regarding the issuance of the Newly Issued Stock Acquisition Rights, please refer to the press release titled “Notice Regarding the Issuance of the 65th to 67th Stock Acquisition Rights (with Exercise Price Adjustment Clauses) through Third-Party Allotment and the Execution of a Purchase Agreement (Commit Issue) for the 1st Unsecured Straight Bonds and Stock Acquisition Rights,” published on July 22, 2025. For details regarding the issuance of the 58th Stock Acquisition Rights, please refer to the press release titled “Notice of the Issuance of New Shares and the 58th Stock Acquisition Rights through Third-party Allotment,” published on May 16, 2022.

1. Background

The terms of issuance for the 58th Series of Stock Acquisition Rights did not include a price adjustment clause whereby the exercise price would be revised in accordance with fluctuations in the market price of the Company’s common shares. However, a price adjustment provision was included, stipulating that if, after issuance, the Company were to deliver common shares at a price below the exercise price of the 58th Series, or issue securities that entitle the holder to receive common shares at such a price, the exercise price would be adjusted downward to match that lower price. (This is a so-called “full ratchet” adjustment clause, as set forth in Item 10, Clause (1) and Clause (2)-3 of the terms of issuance of the 58th Series of Stock Acquisition Rights.)

Furthermore, the adjustment clause provides that if the Company issues stock acquisition rights that entitle the holder to receive common shares and the exercise price of those rights is revised downward to a level below the exercise price of the 58th Series (currently ¥157.5), then the exercise price of the 58th Series will likewise be adjusted downward. (No upward adjustment of the exercise price shall occur under this clause. Also, since no floor price is specified in this adjustment provision, the exercise price may be

revised to below 50% of the closing price on the day prior to the Board resolution approving the issuance of the 58th Series (¥682.) Although the inclusion of this adjustment clause was necessitated through discussions with the allottee, CVI Investments, Inc., the Company believes that the provision offers not only the disadvantage of potential reduction in the amount of funds raised due to a lower exercise price but also the advantage of promoting exercise of the rights.

The Newly Issued Stock Acquisition Rights, approved by the Board of Directors on July 22, 2025, each include a provision whereby the exercise price is revised every two trading days in accordance with the respective terms of issuance.

Given the interaction between this price revision clause and the above-mentioned adjustment clause for the 58th Series, if the exercise price of the Newly Issued Stock Acquisition Rights is revised downward to a level below that of the 58th Series, then the exercise price of the 58th Series will also be adjusted downward accordingly. Based on this overall structure, the 58th Series of Stock Acquisition Rights has come to be deemed a "MSCB, etc." as defined under Article 410 of the Securities Listing Regulations of the Tokyo Stock Exchange.

Going forward, if the Company issues other MSCBs or similar securities in addition to the Newly Issued Stock Acquisition Rights during the remaining term of the 58th Series, the exercise price of the 58th Series will continue to be adjusted such that it matches the lowest exercise price among all outstanding MSCB, etc.

2. Management and Disclosure of the Exercise Status of the 58th Series of Stock Acquisition Rights

As the 58th Series of Stock Acquisition Rights is now deemed to fall under "MSCB, etc.," the Company will disclose information on the exercise price and exercise status of the 58th Series not only in reports on large-scale exercises, but also on a monthly basis alongside disclosures related to the exercise price and exercise status of the Newly Issued Stock Acquisition Rights.

3. Measures Related to Exercise Restrictions on MSCB, etc. Under Securities Listing Regulations

Pursuant to Article 434, Paragraph 1 and Article 436, Paragraphs 1 through 5 of the Securities Listing Regulations established by the Tokyo Stock Exchange, the Company, in principle, shall not permit any Excess Exercise whereby the number of shares acquired by holders of the 58th Series of Stock Acquisition Rights through exercise within a single calendar month, when combined with the number of shares delivered through the conversion of other MSCBs or similar securities, exceeds 10% of the total number of listed shares as of the payment date of the Newly Issued Stock Acquisition Rights.